Predictors of Response to Cyclo-Oxygenase-2 Inhibitors in Osteoarthritis: Pooled Results from Two Identical Trials Comparing Etoricoxib, Celecoxib, and Placebo

Pain Medicine

Volumn 12, Issue 3, 2011, Pages 352-361

  Bingham Iii, Clifton O ^a   Smugar, Steven S ^b   Wang, Hongwei ^b   Peloso, Paul M ^b   Gammaitoni, Arnold ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Demographic Factors; NSAID; Osteoarthritis; Outcome; Predictors; Response

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG USE; FEMALE; FUNCTIONAL ASSESSMENT; HIP OSTEOARTHRITIS; HUMAN; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; PAIN ASSESSMENT; PREDICTOR VARIABLE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 79953053042     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2011.01060.x     Document Type: Article

References (30)

1. Gotzsche PC. Non-steroidal anti-inflammatory drugs. BMJ 2000;320:1058-61.
2. Heller CA, Ingelfinger JA, Goldman P. Nonsteroidal antiinflammatory drugs and aspirin-Analyzing the scores. Pharmacotherapy 1985;5:30-8.
3. Hochberg MC, Dougados M. Pharmacological therapy of osteoarthritis. Best Pract Res Clin Rheumatol 2001;15:583-93.
4. Lister BJ, Poland M, DeLapp RE. Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. Am J Med 1993;95:2S-9S.
5. Towheed T, Shea B, Wells G, Hochberg M. Analgesia and non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the hip. Cochrane Database Syst Rev 2000;CD000517.
6. Watson MC, Brookes ST, Kirwan JR, Faulkner A. Non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the knee. Cochrane Database Syst Rev 2000;CD000142.
7. Huskisson EC, Woolf DL, Balme HW, Scott J, Franklin S. Four new anti-inflammatory drugs: Responses and variations. BMJ 1976;1:1048-9.
8. Pavelka K, Peliskova Z, Stehlikova H, Ratcliffe S, Repas C. Intraindividual differences in pain relief and functional improvement in osteoarthritis with diclofenac or tramadol. Clin Drug Investig 1998;16:421-9.
9. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs-Differences and similarities. N Engl J Med 1991;324:1716-25.
10. Furst DE. Are there differences among nonsteroidal antiinflammatory drugs? Comparing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal antiinflammatory drugs. Arthritis Rheum 1994;37:1-9.
11. Kaplan B, Swain RA. NSAIDs. Are there any differences? Arch Fam Med 1993;2:1167-74.
12. Labrecque G, Bureau JP, Reinberg AE. Biological rhythms in the inflammatory response and in the effects of non-steroidal anti-inflammatory drugs. Pharmacol Ther 1995;66:285-300.
13. Levy RA, Smith DL. Clinical differences among nonsteroidal antiinflammatory drugs: Implications for therapeutic substitution in ambulatory patients. DICP 1989;23:76-85.
14. Palmer SN, Giesecke NM, Body SC, etal. Pharmacogenetics of anesthetic and analgesic agents. Anesthesiology 2005;102:663-71.
15. Stamer UM, Stuber F. The pharmacogenetics of analgesia. Expert Opin Pharmacother 2007;8:2235-45.
16. Bradley JD, Katz BP, Brandt KD. Severity of knee pain does not predict a better response to an antiinflammatory dose of ibuprofen than to analgesic therapy in patients with osteoarthritis. J Rheumatol 2001;28:1073-6.
17. Case JP, Baliunas AJ, Block JA. Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: A randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. Arch Intern Med 2003;163:169-78.
18. Walker JS, Sheather-Reid RB, Carmody JJ, Vial JH, Day RO. Nonsteroidal antiinflammatory drugs in rheumatoid arthritis and osteoarthritis: support for the concept of "responders" and "nonresponders". Arthritis Rheum 1997;40:1944-54.
19. Detora LM, Krupa D, Bolognese J, Sperling RS, Ehrich EW. Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors. J Rheumatol 2001;28:2494-503.
20. Battisti WP, Katz NP, Weaver AL, etal. Pain management in osteoarthritis: A focus on onset of efficacy-A comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials. J Pain 2004;5:511-20.
21. Bingham CO III, Smugar SS, Wang H, Tershakovec AM. Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: Pooled results from two identical trials comparing etoricoxib, celecoxib and placebo. Rheumatology (Oxford) 2009;48:1122-7.
22. Bingham CO III, Sebba AI, Rubin BR, etal. Efficacy and safety of etoricoxib 30mg and celecoxib 200mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford) 2007;46:496-507.
23. Bingham CO III, Bird SR, Smugar SS, Xu X, Tershakovec AM. Responder analysis and correlation of outcome measures: Pooled results from two identical studies comparing etoricoxib, celecoxib, and placebo in osteoarthritis. Osteoarthr Cartil 2008;16:1289-93.
24. Pham T, van der Heijde D, Altman RD, etal. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthr Cartil 2004;12:389-99.
25. Bellamy N. WOMAC: A 20-year experiential review of a patient-centered self-reported health status questionnaire. J Rheumatol 2002;29:2473-6.
26. Gottesdiener K, Schnitzer T, Fisher C, etal. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology (Oxford) 2002;41:1052-61.
27. Bellamy N, Carr A, Dougados M, Shea B, Wells G. Towards a definition of "difference" in osteoarthritis. J Rheumatol 2001;28:427-30.
28. Dworkin RH, Turk DC, Wyrwich KW, etal. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105-21.
29. Ehrich EW, Davies GM, Watson DJ, etal. Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis. J Rheumatol 2000;27:2635-41.
30. Tubach F, Ravaud P, Baron G, etal. Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: The minimal clinically important improvement. Ann Rheum Dis 2005;64:29-33.